About 5 results found for searched term "Kp7-6" (0.125 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M25025 | Vixarelimab | IL Receptor/Related |
| KPL-716 | ||
| Vixarelimab (KPL-716) is a human anti-oncostatin M (OSM) monoclonal antibody that binds to the beta chain of the OSM receptor and inhibits IL-31 and OSM signalling. Vixarelimab can be used in studies of inflammatory skin diseases such as atopic dermatitis and itchy nodular rash. | ||
| M53415 | Kp7-6 | Apoptosis |
| Kp7-6, a Fas mimetic peptide, is a Fas/FasL antagonist. | ||
| M10583 | RRX-001 | NLR |
| ABDNAZ | ||
| Rrx-001 is a hypoxic selective epigenetic factor that has been used as a radiation or chemotherapy sensitizer to induce apoptosis. Rrx-001 is an immune checkpoint inhibitor that down-regulates CD47 and SIRP-α. Rrx-001 is also an effective inhibitor of G6PD with strong antimalarial activity. Rrx-001 inhibits the expression of CD47 in tumor cells by inhibiting c-myC, a positive regulator of CD47. | ||
| M29606 | NSC689857 | EGFR/HER2 |
| NSC689857 is a potent EGFR and SCFSKP2 inhibitor with an IC50 value of 36 μM for Skp2-Cks1. NSC689857 can inhibit p27 ubiquitylation (IC50=30 μM). NSC689857 has varied activity across cancer types, with more activity against leukemia cell lines than others. | ||
| M49905 | KPH2f | URAT1 |
| KPH2f is an orally potent dual URAT1/GLUT9 inhibitor, with IC50s of 0.24 μM and 9.37 μM for URAT1 and GLUT9, respectively.KPH2f had little effect on OAT1 and ABCG2 (IC50s of 32.14 and 26.74 μM, respectively). | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
